<\/p>\n
Shiseido<\/strong>\u2019s net income decreased by 28%<\/strong>, to 11.75 billion yen (75.1 million euros) for the six months ended June 30, from 16.25 billion a year earlier. A decrease due in particular to the increase in operating expenses related to its refocusing on the high-end segment and the sale of its consumer cosmetics activities in Asia, initiated in 2021<\/strong>.<\/p>\n <\/p>\n On Tuesday, the Japanese group said earnings per share fell to 29.4 yen from 40.64. Net sales decreased slightly from 493 billion yen to 494 billion yen.<\/p>\n <\/p>\n <\/p>\n Its sales in the first half of the year notably increased in its two main markets, Japan (+8.2%) and China (+12.8%), where they had been particularly affected previously by health restrictions related to the pandemic.<\/p>\n <\/p>\n On the other hand, revenue declined in the Americas, Asia-Pacific (excluding Japan and China) and EMEA (Europe, Middle East and Africa) regions and stagnated in travel retail (airport shops).<\/p>\n <\/p>\n The company reported an interim dividend of 30 yen for the period under review<\/strong>, which will be paid to shareholders from early September. It plans to pay a final dividend of 30 yen for the year ending December 31, which appears to be less than the 75 yen paid for the previous fiscal year.<\/p>\n <\/p>\n For the end of the fiscal year, Shiseido maintains its objectives with an attributable profit of 28 billion yen (178.3 million euros), which would be a fall of 18.1% over one year<\/strong>, a profit per share of 70.08 yen and net sales of 1,000 billion yen (\u20ac6.4 billion), down 6.3% compared to 2022.<\/p>\n <\/p>\n Finally, despite figures below expectations for the first half of the year, the Group\u2019s equities<\/strong> increased by more than 3%<\/strong> after the announcement of its results.<\/p>\n <\/p>\n Read also >Shiseido announces the merger of its Japan and Pharmaceuticals subsidiaries<\/a><\/p>\nSales pick up in Japan and China<\/h2>\n